GSK1349572 CAS 1051375-16-6 API Active Pharmaceutical Ingredient White To Pale Yellow Solid

Product Description:

Product Name: GSK1349572 CAS NO: 1051375-16-6

Synonyms:

(4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide;

S/GSK1349572;

2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(2,4-difluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-;

Chemical & Physical Properties:

Appearance: White to Pale Yellow Solid

Assay :≥99.0%

Density: 1.53

Melting Point: 188-192℃

Boiling Point: 669.0±55.0℃(Predicted)

Flash Point: 358.4±31.5℃

Vapour Pressure: 0.0±2.1 mmHg at 25℃

Index of Refraction: 1.650

Dolutegravir (DTG) is an FDA-approved drug for the treatment of HIV infection. Dolutegravir is an integrase inhibitor. Known as S/GSK1349572 or just "572" the drug is marketed as Tivicay by GlaxoSmithKline (GSK). In February, 2013 the Food and Drug Administration announced that it would fast track dolutegravir's approval process. On August 13, 2013, dolutegravir was approved by the FDA. On November 4, 2013, dolutegravir was approved by Health Canada. On January 16, 2014, Tivicay was approved by the European Commission for use throughout the European Union.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.